Germany-based biopharmaceutical company Omeicos Therapeutics raised €6.2m ($6.6m) in a series A round featuring SMS Group, a metallurgical plant operator and mechanical engineering firm, on Wednesday.
The round was led by mid-stage investment fund Vesalius Biocapital Partners with the participation of venture capital fund VC Fonds Technology Berlin, public-private venture capital investment firm High-Tech Gruenderfonds (HTGF), and German state-owned development bank KfW Group.
Omeicos is developing a novel molecule for the treatment and prevention of heart disorder atrial fibrillation.
HTGF previously supplied an undisclosed amount of seed funding to Omeicos in 2012. The company has also received €550,000 from Ascenion’s Spinnovator, a grant programme supported by the German Ministry of Education and Research.